藥學雜誌電子報128期 | 合法藥品大搜索

2016年9月30日—Ulipristalacetate為一種具口服活性的合成選擇性黃體素受體調節劑(selectiveprogesteronereceptormodulator(SPRM))，機轉如下：一、子宮肌瘤會比 ...

Chun-Chin Tong1, Chien-Ying Lee1,2 Department of Pharmacy, Chung Shan Medical University Hospital1 Department of Medicine, Chung Shan Medical University2

Uterine fibroids are the most common benign uterine tumors in women of reproductive age. Although most women are asymptomatic, fibroids, according to their type and location, can cause several symptoms and impact quality of life. To date, no medical treatment is able to eliminate fibroids. Ulipristal acetate is an orally active synthetic selective progesterone receptor modulator characterized by a tissue-specific progesterone antagonist effect that reduces the proliferation of leiomyoma cells and induces apoptosis. It was licensed in Europe for preoperative fibroid treatment in 2012. Its pharmacological and pharmacodynamic characteristics, its efficacy and good tolerance make Ulipristal acetate a new important tool in the management of uterine fibroids.